🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mark Knafl

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-3953-2173
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors”.

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors

JAMA Oncology(2022)10.1001/jamaoncol.2022.0212
N/A
1.1DataRank · unranked
40 citations

Suyu Liu, Arvind Dasari, David R. Fogelman, Priya Bhosale, Armeen Mahvash +21 more

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer

npj Precision Oncology(2024)10.1038/s41698-024-00729-0
N/A
0.298DataRank · unranked
5 citations

Li Zhao, Xingzhi Song, Xiaogang Wu, Savitri Krishnamurthy, Takashi Semba +63 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1
N/A
0DataRank · unranked
0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

Prognostic and predictive significance of pre- and post-operative plasma tumor markers in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery: Insights from a single-center study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3539
N/A
0DataRank · unranked
0 citations

Mahmoud Yousef, Mohammad A. Zeineddine, Ichiaki Ito, Saikat Chowdhury, Yue Gu +15 more

Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0019
N/A
0DataRank · unranked
11 citations

Mohammad A. Zeineddine, Betul Beyza Gunes, Andrew J. Pellatt, Mark Knafl, Haifeng Zhu +12 more

Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples

Nature Communications(2025)10.1038/s41467-025-63414-1
N/A
0DataRank · unranked
24 citations

Max Molina Ayala, Sharia Hernandez, Wei Lu, Khaja Khan, Alejandra G. Serrano +69 more

Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.3455
N/A
0DataRank · unranked
11 citations

Rishab Prakash, Paul Edelkamp, Mark Knafl, Anath C. Lionel, Ranjit Nair +94 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331
N/A
0DataRank · unranked
73 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report

Radiotherapy and Oncology(2025)10.1016/j.radonc.2025.111200
N/A
0DataRank · unranked
1 citations

Joanna C. Yang, Carla Hajj, Andrea K. Ng, J.L. Brady, Shuhui Cheng +11 more

Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8557
N/A
0DataRank · unranked
1 citations

Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu, Anaís Malpica +13 more